CA2853220A1 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment - Google Patents
Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment Download PDFInfo
- Publication number
- CA2853220A1 CA2853220A1 CA2853220A CA2853220A CA2853220A1 CA 2853220 A1 CA2853220 A1 CA 2853220A1 CA 2853220 A CA2853220 A CA 2853220A CA 2853220 A CA2853220 A CA 2853220A CA 2853220 A1 CA2853220 A1 CA 2853220A1
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- cer
- compared
- sample
- concentration ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556909P | 2011-11-08 | 2011-11-08 | |
| US61/556,909 | 2011-11-08 | ||
| EP11188328.6 | 2011-11-08 | ||
| EP11188328.6A EP2592423A1 (en) | 2011-11-08 | 2011-11-08 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| PCT/EP2012/071972 WO2013068373A2 (en) | 2011-11-08 | 2012-11-07 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2853220A1 true CA2853220A1 (en) | 2013-05-16 |
Family
ID=45033777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2853220A Abandoned CA2853220A1 (en) | 2011-11-08 | 2012-11-07 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9052328B2 (enExample) |
| EP (3) | EP2592423A1 (enExample) |
| JP (1) | JP6388283B2 (enExample) |
| CN (1) | CN103917876B (enExample) |
| CA (1) | CA2853220A1 (enExample) |
| HK (1) | HK1202157A1 (enExample) |
| WO (1) | WO2013068373A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2667197B1 (en) * | 2012-05-25 | 2015-09-16 | Zora Biosciences OY | Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition |
| WO2015071145A1 (en) * | 2013-11-14 | 2015-05-21 | Nestec S.A. | Lipid biomarkers of healthy ageing |
| BR112016023418A8 (pt) | 2014-04-10 | 2019-12-10 | MEP Equine Solutions LLC | método e kit para a quantificação de ovos de parasitas nas fezes |
| US9347960B2 (en) | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| CN107110939B (zh) | 2014-09-11 | 2021-05-14 | 力保科学公司 | 用于测定心血管疾病或事件的风险参数的系统 |
| WO2016100549A2 (en) | 2014-12-16 | 2016-06-23 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| WO2017029401A1 (en) * | 2015-08-19 | 2017-02-23 | Metanomics Gmbh | Means and methods for diagnosing cardiac disease in a subject |
| US20180306821A1 (en) * | 2015-10-20 | 2018-10-25 | Medimmune, Llc | Diagnostic marker for coronary artery disease |
| US10184932B2 (en) | 2015-12-07 | 2019-01-22 | Zora Biosciences Oy | Use of ceramides and LPLs in diagnosing CVD |
| CN105424841B (zh) * | 2015-12-25 | 2017-11-03 | 齐炼文 | 用于诊断冠状动脉粥样硬化的代谢标志物 |
| CN107014942A (zh) * | 2017-05-05 | 2017-08-04 | 北京骐骥生物技术有限公司 | 利用脂质生物标志物预测糖尿病冠心病的方法 |
| CN107144624B (zh) * | 2017-05-15 | 2021-01-05 | 中国科学院生态环境研究中心 | 甄别二氧化硅颗粒来源的方法 |
| CN114062581A (zh) * | 2017-12-14 | 2022-02-18 | 江苏豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2019119049A1 (en) * | 2017-12-20 | 2019-06-27 | Baker Heart and Diabetes Institute | Method of predicting drug therapeutic responder status and methods of treatment |
| WO2020115288A1 (en) | 2018-12-06 | 2020-06-11 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| CN113533754A (zh) * | 2021-07-12 | 2021-10-22 | 北京市心肺血管疾病研究所 | 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用 |
| WO2024192471A1 (en) * | 2023-03-20 | 2024-09-26 | Baker Heart and Diabetes Institute | Methods of assessing metabolic health |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6210976B1 (en) * | 1997-06-10 | 2001-04-03 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| WO2004038381A2 (en) | 2002-10-25 | 2004-05-06 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
| US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| DE102006034153B4 (de) | 2006-07-24 | 2018-02-08 | Magna powertrain gmbh & co kg | Getriebe |
| US20100179066A1 (en) | 2007-06-07 | 2010-07-15 | Inserm (Institut National De La Santé Et De La Rec | Method for Assessing the Risk of a Cardiovascular Disease and for Diagnosing Dyslipidemia |
| CA3054541C (en) * | 2007-06-08 | 2022-11-29 | Quest Diagnostics Investments Incorporated | Lipoprotein analysis by differential charged-particle mobility |
| EP2048243A1 (en) | 2007-09-24 | 2009-04-15 | sanofi-aventis | Use of clec1B for the determination of cardiovascular and thrombotic risk |
| GB2469244A (en) | 2008-01-28 | 2010-10-06 | Univ Singapore | Lipid tumour profile |
| AU2009224114B2 (en) | 2008-03-12 | 2013-02-21 | Otago Innovation Limited | Biomarkers |
| CN102203606A (zh) | 2008-10-30 | 2011-09-28 | 公共健康研究中心 | 生物标记物 |
| US20110034419A1 (en) * | 2009-06-27 | 2011-02-10 | Musc Foundation For Research Development | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease |
| EP2502068B1 (en) * | 2009-11-17 | 2016-02-10 | Baylor Research Institute | Urinary triaosylceramide (gb3) as a marker of cardiac disease |
| US9110086B2 (en) | 2009-11-27 | 2015-08-18 | Baker Idi Heart And Diabetes Institute Holdings Limited | Lipid biomarkers for stable and unstable heart disease |
| ES2455124T5 (es) | 2010-05-05 | 2018-05-08 | Zora Biosciences Oy | Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca |
| CN103154742B (zh) | 2010-06-20 | 2017-11-21 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| US9664698B2 (en) | 2011-04-08 | 2017-05-30 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
-
2011
- 2011-11-08 EP EP11188328.6A patent/EP2592423A1/en not_active Withdrawn
-
2012
- 2012-11-07 EP EP17150693.4A patent/EP3208617B1/en active Active
- 2012-11-07 HK HK15102644.9A patent/HK1202157A1/xx unknown
- 2012-11-07 US US14/356,594 patent/US9052328B2/en active Active
- 2012-11-07 JP JP2014540426A patent/JP6388283B2/ja active Active
- 2012-11-07 EP EP12781324.4A patent/EP2776841B1/en active Active
- 2012-11-07 WO PCT/EP2012/071972 patent/WO2013068373A2/en not_active Ceased
- 2012-11-07 CN CN201280054323.8A patent/CN103917876B/zh active Active
- 2012-11-07 CA CA2853220A patent/CA2853220A1/en not_active Abandoned
-
2015
- 2015-05-27 US US14/722,964 patent/US9423406B2/en active Active
-
2016
- 2016-07-14 US US15/210,048 patent/US9863965B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6388283B2 (ja) | 2018-09-12 |
| EP2776841B1 (en) | 2017-01-11 |
| JP2014532885A (ja) | 2014-12-08 |
| US9423406B2 (en) | 2016-08-23 |
| US9052328B2 (en) | 2015-06-09 |
| EP3208617B1 (en) | 2021-02-24 |
| WO2013068373A2 (en) | 2013-05-16 |
| US9863965B2 (en) | 2018-01-09 |
| EP3208617A2 (en) | 2017-08-23 |
| CN103917876B (zh) | 2018-02-02 |
| CN103917876A (zh) | 2014-07-09 |
| EP2776841A2 (en) | 2014-09-17 |
| WO2013068373A3 (en) | 2013-07-18 |
| US20140295467A1 (en) | 2014-10-02 |
| US20150260737A1 (en) | 2015-09-17 |
| HK1202157A1 (en) | 2015-09-18 |
| EP3208617A3 (en) | 2017-11-01 |
| US20160320418A1 (en) | 2016-11-03 |
| EP2592423A1 (en) | 2013-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12270816B2 (en) | Lipidomic biomarkers for identification of high-risk coronary artery disease patients | |
| US9459265B2 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment | |
| US9863965B2 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment | |
| CA2798238C (en) | Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20181107 |